Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label 6-Week Ledipasvir/Sofosbuvir in Acute Genotype 1 or 4 HCV with Chronic HIV-1 Co-Infection
2014-004812-12Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ledipasvir in hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Primary endpoint: Sustained virological response at 12 weeks after treatment (SVR12). Started Feb 2015; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-004812-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004812-12.